A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan (Q33980368)

30 July 2017

A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan (English)

1 reference

multicenter clinical trial

30 July 2017

0 references

1 reference

1

Shigeru Kohno

1 reference

30 July 2017

Toru Masaoka

2

1 reference

30 July 2017

Hideyo Yamaguchi

3

1 reference

30 July 2017

Takeshi Mori

4

1 reference

30 July 2017

Akio Urabe

5

1 reference

30 July 2017

Akira Ito

6

1 reference

30 July 2017

Yoshihito Niki

7

1 reference

30 July 2017

Hideo Ikemoto

8

1 reference

30 July 2017

1 January 2004

1 reference

Scandinavian Journal of Infectious Diseases

30 July 2017

1 reference

30 July 2017

36

1 reference

30 July 2017

5

1 reference

30 July 2017

372-379

1 reference

Practice guidelines for the treatment of fungal infections. For the Mycoses Study Group. Infectious Diseases Society of America

30 July 2017

1 reference

https://api.crossref.org/works/10.1080%2F00365540410020406

Guidelines for the investigation of invasive fungal infections in haematological malignancy and solid organ transplantation. British Society for Medical Mycology

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540410020406

Therapeutic outcome in invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540410020406

Fungal infections in solid-organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540410020406

Update on drug interactions with azole antifungal agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540410020406

A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540410020406

In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540410020406

Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540410020406

Efficacy of FK463, a (1,3)-beta-D-glucan synthase inhibitor, in disseminated azole-resistant candida albicans infection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540410020406

Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540410020406

Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540410020406

Resistance of yeasts to azole-derivative antifungals

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540410020406

Resistance of Candida species to fluconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540410020406

Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540410020406

21 January 2018

Intravenous itraconazole

1 reference

https://api.crossref.org/works/10.1080%2F00365540410020406

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540410020406

Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540410020406

A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540410020406

Chronic forms of pulmonary aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540410020406

Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540410020406

10.1080/00365540410020406

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference